Back to top
more

Collegium Pharmaceutical (COLL)

(Real Time Quote from BATS)

$35.00 USD

35.00
47,772

-0.45 (-1.27%)

Updated Apr 18, 2024 12:21 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Collegium Pharmaceutical (COLL) Stock Sinks As Market Gains: What You Should Know

Collegium Pharmaceutical (COLL) closed at $38.79 in the latest trading session, marking a -1.6% move from the prior day.

Humana (HUM), DUOS Unveil Program to Improve Veterans' Health

Humana (HUM) collaborates with DUOS to develop a program that aims to provide personalized care and assure the well-being of Louisiana's Veteran community, who have a HUM MA plan and suffer from chronic conditions.

Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks.com featured highlights AppLovin, Kaiser Aluminum, Collegium Pharmaceutical, EMCOR Group and Textron

AppLovin, Kaiser Aluminum, Collegium Pharmaceutical, EMCOR Group and Textron have been highlighted in this Screen of The Week article.

Strength Seen in Aquestive Therapeutics (AQST): Can Its 16.0% Jump Turn into More Strength?

Aquestive Therapeutics (AQST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Nilanjan Choudhury headshot

Time to Get These 5 Top Relative Price Strength Stocks

APP, KALU, COLL, EME and TXT are five stocks with explosive relative price strength.

3 Reasons Why Collegium Pharmaceutical (COLL) Is a Great Growth Stock

Collegium Pharmaceutical (COLL) could produce exceptional returns because of its solid growth attributes.

Encompass Health (EHC), Piedmont to Build Loganville Facility

Encompass Health (EHC) partners with Piedmont to construct a 40-bed inpatient rehabilitation hospital in Georgia to better serve the rehabilitative care needs of the state and solidify its footprint.

Humana (HUM) Inks Value-Based Deal to Offer Better Kidney Care

Humana (HUM) expands ties with Strive to offer high-quality kidney care to its Medicare Advantage members and thereby, aims to increase the customer base of the relevant business line.

Here's Why You Should Invest in Aldeyra (ALDX) Stock Now

Here, we discuss some reasons why investing in Aldeyra Therapeutics (ALDX) stock now may turn out to be a prudent move.

Are You Looking for a Top Momentum Pick? Why Collegium Pharmaceutical (COLL) is a Great Choice

Does Collegium Pharmaceutical (COLL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Best Value Stocks to Buy for February 29th

UGP, HMC and COLL made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 29, 2023.

Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q4 Earnings

The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Analysts Estimate Recursion Pharmaceuticals (RXRX) to Report a Decline in Earnings: What to Look Out for

Recursion Pharmaceuticals (RXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock?

ImmunoGen (IMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Why Collegium Pharmaceutical (COLL) Could Beat Earnings Estimates Again

Collegium Pharmaceutical (COLL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Collegium Pharmaceutical (COLL) Stock Might be a Great Pick

Collegium Pharmaceutical (COLL) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.

Collegium (COLL) Shares Rise on Financial Outlook for 2024

Collegium (COLL) reports financial guidance for full-year 2024 and business updates. Shares of the company rise on the same.

Strength Seen in Collegium Pharmaceutical (COLL): Can Its 8.4% Jump Turn into More Strength?

Collegium Pharmaceutical (COLL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings

While the top- and bottom-line numbers for Collegium Pharmaceutical (COLL) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth

Catalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Collegium Pharmaceutical (COLL) Reports Next Week: Wall Street Expects Earnings Growth

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exscientia PLC Sponsored ADR (EXAI) Stock Jumps 13.5%: Will It Continue to Soar?

Exscientia PLC Sponsored ADR (EXAI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.